2. Ansaldi F, Icardi G, Gasparini R, et al. New A/H3N2 influenza variant: a small genetic evolution but a heavy burden on the Italian population during the 2004–2005 season. J Clin Microbiol. 2005;43:3027–9. [PMC free article] [PubMed] 3. Ng TP, Pwee KH, Niti M, et al. Influenza in Singapore: assessing the burden of illness in the community. Ann Acad Med Singapore. 2002;31:182–8. [PubMed] 4. Fiore AE, Shay DK, Broder K, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep. 2008;57:1–60. [PubMed] 5. Ruf BR, Szucs T. Reducing the burden of influenza-associated complications with antiviral therapy. Infection. 2009;37:186–96. [PubMed] 6. Meier CR, Napalkov PN, Wegmuller Y, et al. Population-based study on incidence, risk factors, clinical complications and drug utilisation associated with influenza in the United Kingdom. Eur J Clin Microbiol Infect Dis. 2000;19:834–42. [PubMed] 7. Simonsen L, Fukuda K, Schonberger LB, et al. The impact of influenza epidemics on hospitalizations. J Infect Dis. 2000;181:831–7. [PubMed] 8. Pitman RJ, Melegaro A, Gelb D, et al. Assessing the burden of influenza and other respiratory infections in England and Wales. J Infect. 2007;54:530–8. [PubMed]
9. Korsman K. Vaccines. In: Kamps BS, Hoffmann C, Preiser E, editors. Influenza Report. 2006. pp. 127–49. Paris, France: Flying Publisher.
10. Mereckiene J, Cotter S, Weber JT, et al. Low coverage of seasonal influenza vaccination in the elderly in many European countries. Euro Surveill. 2008;13 pii=19001. [PubMed] 11. CDC. State-specific influenza vaccination coverage among adults—United States, 2006–07 influenza season. MMWR Morb Mortal Wkly Rep. 2008;57:1033–9. [PubMed] 12. CDC. Influenza vaccination coverage among children aged 6–59 months—eight immunization information system sentinel sites, United States, 2007–08 influenza season. MMWR Morb Mortal Wkly Rep. 2008;57:1043–6. [PubMed] 13. Harper SA, Bradley JS, Englund JA, et al. Seasonal influenza in adults and children—diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:1003–32. [PubMed] 14. Stephenson I, Clarke TW, Pareek M. Guidelines for the treatment and prevention of seasonal influenza: a comparative review of antiviral recommendations in the European Union. Abstracts of the Third European Influenza Conference; 2008; Vilamoura. Abstract 6-002. European Scientific Working Group on Influenza, Antwerp, Belgium. [PubMed] 15. Nicholson KG, Aoki FY, Osterhaus AD, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet. 2000;355:1845–50. [PubMed] 16. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA. 2000;283:1016–24. [PubMed] 17. Aoki FY, Macleod MD, Paggiaro P, et al. Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother. 2003;51:123–9. [PubMed] 18. Kaiser L, Wat C, Mills T, et al. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med. 2003;163:1667–72. [PubMed] 19. Whitley RJ, Hayden FG, Reisinger KS, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J. 2001;20:127–33. [PubMed] 20. Johnston SL, Ferrero F, Garcia ML, et al. Oral oseltamivir improves pulmonary function and reduces exacerbation frequency for influenza-infected children with asthma. Pediatr Infect Dis J. 2005;24:225–32. [PubMed] 21. Tamura D, Miura T, Kikuchi Y. Oseltamivir phosphate in infants under 1 year of age with influenza infection. Pediatr Int. 2005;47:484. [PubMed] 23. Singh S, Barghoorn J, Bagdonas A, et al. Clinical benefits with oseltamivir in treating influenza in adult populations: results of a pooled and subgroup analysis. Clin Drug Invest. 2003;23:561–9. [PubMed] 24. Lin JT, Yu XZ, Cui DJ, et al. A multicentre, randomized, controlled trial of oseltamivir in the treatment of influenza in a high-risk Chinese population. Curr Med Res Opin. 2006;22:75–82. [PubMed] 25. McGeer A, Green KA, Plevneshi A, et al. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis. 2007;45:1568–75. [PubMed]
26. Hassan K, Drews S, Blair J, et al. Antiviral therapy improves outcome of influenza infections in patients requiring admission to intensive care. Abstracts of the Forty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy; 2009; San Francisco. Washington, DC, USA: American Society for Microbiology; Abstract V-537.
27. Lee N, Chan PK, Hui DS, et al. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis. 2009;200:492–500. [PubMed]
28. Lee N, Choi K, Chan P, et al. Outcomes of adults hospitalized with influenza, 2007–2008. Abstracts of the Forty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy; 2009; San Francisco. Washington, DC, USA: American Society for Microbiology; Abstract V-1074k.
29. Chemaly RF, Ghosh S, Bodey GP, et al. Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center. Medicine (Baltimore) 2006;85:278–87. [PubMed] 30. Nichols WG, Guthrie KA, Corey L, et al. Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis. 2004;39:1300–6. [PubMed] 31. Khanna N, Steffen I, Studt JD, et al. Outcome of influenza infections in outpatients after allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 2009;11:100–5. [PubMed] 32. Chemaly RF, Torres HA, Aguilera EA, et al. Neuraminidase inhibitors improve outcome of patients with leukemia and influenza: an observational study. Clin Infect Dis. 2007;44:964–7. [PubMed] 33. Machado CM, Boas LS, Mendes AV, et al. Use of oseltamivir to control influenza complications after bone marrow transplantation. Bone Marrow Transplant. 2004;34:111–4. [PubMed] 34. Peters PH, Moscona A, Schulman KL, et al. Study of the impact of oseltamivir on the risk for pneumonia and other outcomes of influenza, 2000–2005. Medscape J Med. 2008;10:131. [PubMed] 35. Blumentals WA, Schulman KL. Impact of oseltamivir on the incidence of secondary complications of influenza in adolescent and adult patients: results from a retrospective population-based study. Curr Med Res Opin. 2007;23:2961–70. [PubMed] 36. Barr CE, Schulman K, Iacuzio D, et al. Effect of oseltamivir on the risk of pneumonia and use of health care services in children with clinically diagnosed influenza. Curr Med Res Opin. 2007;23:523–31. [PubMed] 37. Nordstrom BL, Sung I, Suter P, et al. Risk of pneumonia and other complications of influenza-like illness in patients treated with oseltamivir. Curr Med Res Opin. 2005;21:761–8. [PubMed] 38. Gums JG, Pelletier EM, Blumentals WA. Oseltamivir and influenza-related complications, hospitalization and healthcare expenditure in healthy adults and children. Expert Opin Pharmacother. 2008;9:151–61. [PubMed] 39. Piedra PA, Schulman KL, Blumentals WA. Effects of oseltamivir on influenza-related complications in children with chronic medical conditions. Pediatrics. 2009;124:170–8. [PubMed] 40. Majid M, Curkendall S, Blumentals WA. The influence of oseltamivir on the risk of stroke after influenza infection. Cardiology. 2009;113:98–107. [PMC free article] [PubMed] 41. Casscells SW, Granger E, Kress AM, et al. Use of oseltamivir after influenza infection is associated with reduced incidence of recurrent adverse cardiovascular outcomes among military health system beneficiaries with prior cardiovascular disease. Circ Cardiovasc Qual Outcomes. 2009;2:108–15. [PubMed] 42. Orzeck EA, Shi N, Blumentals WA. Oseltamivir and the risk of influenza-related complications and hospitalizations in patients with diabetes. Clin Ther. 2007;29:2246–55. [PubMed] 43. Welliver R, Monto AS, Carewicz O, et al. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA. 2001;285:748–54. [PubMed] 44. Hayden FG, Belshe R, Villanueva C, et al. Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. J Infect Dis. 2004;189:440–9. [PubMed] 45. Hayden FG, Atmar RL, Schilling M, et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med. 1999;341:1336–43. [PubMed] 46. Peters PH, Jr, Gravenstein S, Norwood P, et al. Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population. J Am Geriatr Soc. 2001;49:1025–31. [PubMed]
47. Reisinger K, Marcadis I, Cupelli LA. Abstracts of the Options for the Control of Influenza VI Conference, Toronto, Canada, 2007. Oseltamivir for prevention of seasonal influenza in children. Abstract P1309. MediTech Media Conferencing, Inc., Atlanta, GA, USA.
48. Ison MG, Szakaly P, Shapira MY, et al. Reduced incidence of seasonal influenza with oseltamivir prophylaxis in solid organ transplant recipients. Abstracts of the American Transplant Congress; 2009; Boston. Abstract 483. http://www.abstracts2view.com/atc/ (9 November 2009, date last accessed) 49. McKimm-Breschkin J, Trivedi T, Hampson A, et al. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob Agents Chemother. 2003;47:2264–72. [PMC free article] [PubMed] 50. Aoki FY, Boivin G, Roberts N. Influenza virus susceptibility and resistance to oseltamivir. Antivir Ther. 2007;12:603–16. [PubMed] 51. Kiso M, Mitamura K, Sakai-Tagawa Y, et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet. 2004;364:759–65. [PubMed] 52. Roberts NA. Treatment of influenza with neuraminidase inhibitors: virological implications. Philos Trans R Soc Lond B Biol Sci. 2001;356:1895–7. [PMC free article] [PubMed] 53. Gubareva LV, Kaiser L, Matrosovich MN, et al. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J Infect Dis. 2001;183:523–31. [PubMed]
54. Jackson HC, Roberts N, Wang ZM, et al. Management of influenza: use of new antivirals and resistance in perspective. Clin Drug Invest. 2000;20:447–54.
55. Carr J, Ives J, Kelly L, et al. Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo. Antiviral Res. 2002;54:79–88. [PubMed] 56. Ives JA, Carr JA, Mendel DB, et al. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res. 2002;55:307–17. [PubMed] 57. Herlocher ML, Carr J, Ives J, et al. Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets. Antiviral Res. 2002;54:99–111. [PubMed] 58. Herlocher ML, Truscon R, Elias S, et al. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J Infect Dis. 2004;190:1627–30. [PubMed] 59. Ward P, Small I, Smith J, et al. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother. 2005;55(Suppl 1):i5–21. [PubMed] 60. Bouvier NM, Lowen AC, Palese P. Oseltamivir-resistant influenza A viruses transmit efficiently among guinea pigs by direct contact but not by aerosol. J Virol. 2008;82:10052–8. [PMC free article] [PubMed] 61. Monto AS, Kimm-Breschkin JL, Macken C, et al. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother. 2006;50:2395–402. [PMC free article] [PubMed] 62. Mungall BA, Xu X, Klimov A. Surveillance of influenza isolates for susceptibility to neuraminidase inhibitors during the 2000–2002 influenza seasons. Virus Res. 2004;103:195–7. [PubMed] 63. Neuraminidase Inhibitor Susceptibility Network (NISN) Monitoring of neuraminidase inhibitor resistance among clinical influenza virus isolates in Japan during the 2003–2006 influenza seasons. Wkly Epidemiol Rec. 2007;82:149–50. [PubMed]
64. Lackenby A, Baldevarona J, Collins P, et al. European surveillance network for influenza antiviral resistance (VIRGIL). Abstracts of the Options for the Control of Influenza VI Conference; 2007; Toronto. Abstract P932. MediTech Media Conferencing, Inc., Atlanta, GA, USA.
65. Sheu TG, Deyde VM, Okomo-Adhiambo M, et al. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother. 2008;52:3284–92. [PMC free article] [PubMed] 66. Stephenson I, Democratis J, Lackenby A, et al. Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children. Clin Infect Dis. 2009;48:389–96. [PubMed]
68. Lackenby A, Lakhman D, Sadler C, et al. A European surveillance network for influenza antiviral resistance (VIRGIL). Abstracts of the Third European Influenza Conference; 2008; Vilamoura. Abstract 5-031. European Scientific Working Group on Influenza, Antwerp, Belgium.
69. Meijer A, Lackenby A, Hungnes O, et al. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007–08 season. Emerg Infect Dis. 2009;15:552–60. [PMC free article] [PubMed]
74. Meijer A, Dijkstra F, Donker GA, et al. Emergence of oseltamivir resistant influenza A(H1N1) viruses in the Netherlands during the winter 2007/2008. Abstracts of the Third European Influenza Conference; 2008; Vilamoura. Abstract 6-021. European Scientific Working Group on Influenza, Antwerp, Belgium.
75. Mosnier A, Escuret V, Enouf V, et al. Emergence of A (H1N1) influenza viruses resistant to oseltamivir during the 2007/2008 season: spatio-temporal trend and clinical impact in France. Abstracts of the Third European Influenza Conference; 2008; Vilamoura. Abstract 6-026. European Scientific Working Group on Influenza, Antwerp, Belgium.
76. Hauge SH, Dudman S, Borgen K, et al. Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007–08. Emerg Infect Dis. 2009;15:155–62. [PMC free article] [PubMed] 77. Dharan NJ, Gubareva LV, Meyer JJ, et al. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA. 2009;301:1034–41. [PubMed]
78. Paget WJ, Meerhoff TJ, Hungnes O, et al. Oseltamivir resistant influenza A(H1N1) viruses and baseline patient clinical characteristics during the 2007/2008 influenza season in Europe. Abstracts of the Third European Influenza Conference; 2008; Vilamoura. Abstract 6-010. European Scientific Working Group on Influenza, Antwerp, Belgium.
79. Kramarz P, Monnet D, Nicoll A, et al. Use of oseltamivir in 12 European countries between 2002 and 2007 - lack of association with the appearance of oseltamivir-resistant influenza A(H1N1) viruses. Euro Surveill. 2009;14 pii=19112. [PubMed]
80. Bragstadt K, Astrup BS, Jensen TG, et al. Fatal influenza due to oseltamivir resistant H1N1 with full characterization using whole viral genome sequencing. Abstracts of the Third European Influenza Conference; 2008; Vilamoura. Abstract 6-006. European Scientific Working Group on Influenza, Antwerp, Belgium.
81. van der Vries E, van den Berg B, Schutten M. Fatal oseltamivir-resistant influenza virus infection. N Engl J Med. 2008;359:1074–6. [PubMed] 82. Gooskens J, Jonges M, Claas EC, et al. Morbidity and mortality associated with nosocomial transmission of oseltamivir-resistant influenza A(H1N1) virus. JAMA. 2009;301:1042–6. [PubMed] 83. Bhat N, Wright JG, Broder KR, et al. Influenza-associated deaths among children in the United States, 2003–2004. N Engl J Med. 2005;353:2559–67. [PubMed] 84. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003;289:179–86. [PubMed] 85. Toovey S, Rayner CR, Prinssen E, et al. Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review. Drug Saf. 2008;31:1097–114. [PubMed] 86. Smith JR, Sacks S. Incidence of neuropsychiatric adverse events in influenza patients treated with oseltamivir or no antiviral treatment. Int J Clin Pract. 2009;63:596–605. [PubMed] 87. Casscells SW, Granger E, Kress AM, et al. The association between oseltamivir use and adverse neuropsychiatric outcomes among TRICARE beneficiaries, ages 1 through 21 years diagnosed with influenza. Int J Adolesc Med Health. 2009;21:79–89. [PubMed] 88. Huang YC, Li WC, Tsao KC, et al. Influenza-associated central nervous system dysfunction in Taiwanese children: clinical characteristics and outcomes with and without administration of oseltamivir. Pediatr Infect Dis J. 2009;28:647–8. [PubMed] 89. Schentag JJ, Hill G, Chu T, et al. Similarity in pharmacokinetics of oseltamivir and oseltamivir carboxylate in Japanese and Caucasian subjects. J Clin Pharmacol. 2007;47:689–96. [PubMed]
90. Gieschke R, Dutkowski R, Smith J, et al. Similarity in the pharmacokinetics of oseltamivir and oseltamivir carboxylate in Japanese and Caucasian children. Abstracts of the Options for the Control of Influenza VI Conference; 2007; Toronto. Abstract P921. MediTech Media Conferencing, Inc., Atlanta, GA, USA.
91. Jhee SS, Yen M, Ereshefsky L, et al. Low penetration of oseltamivir and its carboxylate into cerebrospinal fluid in healthy Japanese and Caucasian volunteers. Antimicrob Agents Chemother. 2008;52:3687–93. [PMC free article] [PubMed] 92. Toovey S. Influenza-associated central nervous system dysfunction: a literature review. Travel Med Infect Dis. 2008;6:114–24. [PubMed] 93. Dutkowski R, Thakrar B, Froehlich E, et al. Safety and pharmacology of oseltamivir in clinical use. Drug Saf. 2003;26:787–801. [PubMed] 94. Vu D, Peck AJ, Nichols WG, et al. Safety and tolerability of oseltamivir prophylaxis in hematopoietic stem cell transplant recipients: a retrospective case-control study. Clin Infect Dis. 2007;45:187–93. [PubMed] 95. Kashiwagi S, Kudoh S, Watanabe A, et al. [Clinical efficacy and safety of the selective oral neuraminidase inhibitor oseltamivir in treating acute influenza -placebo-controlled double-blind multicenter phase III trial] Kansenshogaku Zasshi. 2000;74:1044–61. [PubMed]